443 related articles for article (PubMed ID: 16424187)
1. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
[TBL] [Abstract][Full Text] [Related]
2. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
3. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R; Hayakawa Y; Nelson A; Sivakumar PV; Hughes S; Smyth MJ; Lanier LL
J Immunol; 2005 Aug; 175(4):2167-73. PubMed ID: 16081783
[TBL] [Abstract][Full Text] [Related]
4. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
5. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
[TBL] [Abstract][Full Text] [Related]
6. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.
Ni J; Miller M; Stojanovic A; Garbi N; Cerwenka A
J Exp Med; 2012 Dec; 209(13):2351-65. PubMed ID: 23209317
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
9. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.
Han Y; Guo Q; Zhang M; Chen Z; Cao X
J Immunol; 2009 Jan; 182(1):111-20. PubMed ID: 19109141
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma.
Chang WC; Li CH; Chu LH; Huang PS; Sheu BC; Huang SC
Int J Gynecol Cancer; 2016 Jan; 26(1):156-62. PubMed ID: 26512789
[TBL] [Abstract][Full Text] [Related]
11. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
Smyth MJ; Swann J; Kelly JM; Cretney E; Yokoyama WM; Diefenbach A; Sayers TJ; Hayakawa Y
J Exp Med; 2004 Nov; 200(10):1325-35. PubMed ID: 15545356
[TBL] [Abstract][Full Text] [Related]
12. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
13. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
14. Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner.
Zhou H; Chen L; You Y; Zou L; Zou P
Autoimmunity; 2010 Jun; 43(4):299-307. PubMed ID: 20166879
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
16. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
[TBL] [Abstract][Full Text] [Related]
17. CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40.
Chen Y; Sun R; Wu X; Cheng M; Wei H; Tian Z
J Innate Immun; 2016; 8(1):30-42. PubMed ID: 26067079
[TBL] [Abstract][Full Text] [Related]
18. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
19. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
